Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo
Patents for A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
11/2005
11/03/2005DE102004017705A1 Ferromagnetische Kohlenstoff-Nanoröhren, die Biomoleküle tragen, Verfahren zu deren Herstellung und deren Verwendung in Diagnose und Therapie Ferromagnetic carbon nanotubes carrying biomolecules, processes for their preparation and their use in diagnosis and therapy
11/03/2005CA2563619A1 Multimodality nanostructures, methods of fabrication thereof, and methods of use thereof
11/02/2005EP1590434A2 Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods
11/02/2005EP1590317A1 ENANTIOMER-PURE (4S,8S)- AND (4R, 8R)-4-P-NITROBENZYL-8-METHYL-3, 6, 9-TRIAZA- SP 3 /sp N, SP 6 /SP N, SP 9 /SP N-TRICARBOXYMETHYL-1, 11-UNDECANOIC ACID AND DERIVATIVES THEREOF, METHOD FOR PRODUCING THEM, AND THEIR USE FOR PRODUCING PHARMACEUTICAL AGENTS
11/02/2005EP1590007A1 Improved radiometal complex compositions
11/02/2005EP1590005A1 Conjugates of enantiomer-pure (4s,8s)- and (4r,8r)-4-p-benzyl-8-methyl-3,6,9-triaza- sp 3 /sp n, sp 6 /sp n, sp 9 /sp n-tricarboxymethyl-1,11-undecanoic acid with biomolecules, method for the production thereof and their use for producing pharmaceutical agents
11/02/2005EP1430071A4 Secreted and cell surface genes expressed in benign and malignant colorectal tumors
11/02/2005EP1268524B1 Binding peptides for carcinoembryonic antigen (cea)
11/02/2005EP1117443B1 Peptide-based carrier devices for stellate cells
11/02/2005CN1689646A Combination therapies for B-cell lynphomas comprising administration of anti-CD20 antibody
11/02/2005CN1689645A Combination therapies for B-cell lynphomas comprising administration of anti-CD20 antibody
11/02/2005CN1689644A Combination therapies for B-cell lynphomas comprising administration of anti-CD20 antibody
11/02/2005CN1225451C Aliphatic acid metabolic imaging agent beta-methyl-15-parafluoro [18F] phenyl-pentadecanoic acid and synthesizing method thereof
11/02/2005CN1225287C Stabilized radiopharmaceutical composition
11/01/2005US6960614 Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids
10/2005
10/27/2005WO2005100612A2 Bacteriophage imaging of inflammation
10/27/2005WO2005100404A1 Prostate cancer diagnosis and treatment
10/27/2005WO2005099776A2 Steroid sparing agents and methods of using same
10/27/2005WO2005099775A2 Labeled anwexin for predicting the response to a therapeutic regimen
10/27/2005WO2005099773A1 Use of erythropoietin for treatment of cancer
10/27/2005WO2005072781A3 Method and kit for the production of particles labelled with rhenium-188
10/27/2005WO2005060375A3 Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like protein
10/27/2005WO2004073648A3 Composition and methods for inhibiting cell survival
10/27/2005WO2004064760A3 Aptamer therapeutics useful in ocular pharmacotherapy
10/27/2005US20050238584 Sterically stabilized liposomes with hydrophilic polymers on surface; computed tomography
10/27/2005US20050238579 Human g protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure
10/27/2005US20050238578 Administering anticarcinogenic agent and chelate complex of macrocyclic aminophosphonic acid and radionuclide such as samarium ethylenediaminetetramethylenephosphonic acid (EDTMP) to replace total body irradiation;antiproliferative agents; autoimmune, infectious, metabolic or genetic disorders
10/27/2005US20050238577 Isolation of epithelial cells or their biochemical contents from excreta after in vivo isotopic labeling
10/27/2005US20050238576 Delivery methods, systems and components for use with radiopharmaceutical substances
10/27/2005CA2606138A1 Prostate cancer diagnosis and treatment
10/27/2005CA2561364A1 Steroid sparing agents and methods of using same
10/26/2005EP1588162A2 Hsc70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease
10/26/2005EP1588145A2 Methods, mixtures, kits and compositions pertaining to analyte determination
10/26/2005EP1587944A1 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
10/26/2005EP1587836A2 Cancerous disease modifying antibodies
10/26/2005EP1587550A2 Methods and compositions for administering therapeutic and diagnostic agents
10/26/2005EP1587549A2 Radiolabelled tissue factor binding agent and the use thereof
10/26/2005EP1587547A2 Amyloid-binding, metal-chelating agents
10/26/2005EP1587536A1 Agents for the diagnosis and treatment of tumours that expose altered proteins on the cell surface
10/26/2005EP1587525A2 Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
10/26/2005EP1444264A4 Methods and materials for targeting and affecting selected cells
10/25/2005US6958141 Rhenium and technetium complexes containing a hypoxia-localizing moiety
10/20/2005WO2005098024A1 In vivo measurement of the relative fluxes through ribonucleotide reductase vs. deoxyribonucleoside pathways using isotopes
10/20/2005WO2005097672A2 Method for the production of carbon nanotubes that are ferromagnetically filled in part and carry biomolecules, and use thereof in diagnosis and therapy
10/20/2005WO2005097211A2 Compositions as adjuvants to improve immune responses to vaccines and methods of use
10/20/2005WO2005097210A1 Bioresponsive polymer system for delivery of microbicides
10/20/2005WO2005097209A1 Light emitting molecules and organic light emitting devices including light emitting molecules
10/20/2005US20050232924 Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
10/20/2005US20050232861 Microfluidic apparatus and method for synthesis of molecular imaging probes including FDG
10/20/2005US20050232860 Use of edg-receptor agonists for the treatment of hypertension
10/20/2005CA2561174A1 Bioresponsive polymer system for delivery of microbicides
10/20/2005CA2560941A1 Compositions as adjuvants to improve immune responses to vaccines and methods of use
10/19/2005EP1586584A1 Modulators of beta-amyloid peptide aggregation comprising D-amino acids
10/19/2005EP1585770A2 Recognition molecules for the treatment and detection of tumours
10/19/2005EP1585549A2 Improved gastrin releasing peptide compounds
10/19/2005EP0968013B1 Coated implantable medical device
10/19/2005CN1684975A Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure
10/19/2005CN1684973A Compound binding to leukocytes and medicinal composition containing the compound in labeled state as the active ingredient
10/19/2005CN1684702A Method of treating tumors
10/19/2005CN1683377A 99m Tc marked polyamine complex as tumor diagnosing developing agent and its preparation
10/19/2005CN1223378C Cyclodextrin containing glycopeptides antibiotic pharmaceutical compositions
10/13/2005WO2005094897A2 Pegylated ion channel modulating compounds
10/13/2005WO2005094327A2 Isolation of epithelial cells or their biochemical contents from excreta after in vivo isotopic labeling
10/13/2005US20050227985 Folate mimetics and folate-receptor binding conjugates thereof
10/13/2005US20050227979 E.g., 1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-piperidine and 1-[4-(1-Isopropyl-piperidin-4-yloxy)-benzyl]-azepane; these compounds modulate the activity of the histamine receptor, specifically the H3 receptor, without the inherent problems associated with the presence of an imidazolyl moiety
10/13/2005US20050227916 Administering carrier molecule such as albumin conjugated to mannose-6-phosphate; particularly targeting Hepatic Stellate Cells (HSC); glomeruloscherosis, interstitial fibrosis, lung fibrosis, atherosclerosis, Crohn's disease, colitis ulcerosa, glomerulonephritis and sepsis; diagnosis
10/13/2005US20050227910 Local regional chemotherapy and radiotherapy using in situ hydrogel
10/13/2005US20050226883 Humanized antibody
10/13/2005US20050226813 Labelled somatostatin analogs backbone cyclized through metal complexation
10/13/2005US20050226812 Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like proteins
10/13/2005US20050226811 Radioactive iodine-labeled compound
10/13/2005US20050226810 Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and MRI diagnosis
10/13/2005CA2561733A1 Pegylated ion channel modulating compounds
10/12/2005EP1583565A1 Enhanced scintigraphic imaging agents for imaging of infection and inflammation
10/12/2005EP1583564A2 Improved linkers for pharmaceutical compounds
10/12/2005EP1583563A2 Method for the production of hyperpolarized 129xe
10/12/2005EP1359943B1 Biotin-derivates and their conjugates with chelating agents
10/12/2005EP1259814B1 Bcmp-7 as marker for diagnosis of breast cancer
10/12/2005CN1680409A Diphospho-acid complex of radiative technetium-99m marked oxazole phosphinic acid
10/12/2005CN1680383A Indicated tetraodotoxin, preparation and use thereof
10/12/2005CN1679970A Preparation of radiative immune guiding operating medicine of colorectal disease
10/12/2005CN1679969A Medicine of vasoactive peptide derivative containing SN3 ligand and its making method
10/11/2005US6953855 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
10/11/2005US6953674 Inhibitors of human plasmin derived from the kunitz domains
10/11/2005US6953658 Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer
10/11/2005US6953575 Methods of treating central nervous system disorders using viral vectors
10/11/2005US6953568 Administering biological conjugates that bind preferentially to endothelial protein C receptor(EPCR), to endothelial cells of vascular systems; genetic translocation; drug delivery
10/11/2005US6953567 Radiolabeling peptides by reacting thiol-containing peptides with an F-18-bound labelling reagent which also has a group that is reactive with thiols; targeted to a tissue using bispecific antibodies
10/11/2005CA2167921C Biodegradable particles
10/06/2005WO2005093048A1 Cancerous disease modifying antibodies
10/06/2005WO2005092928A1 Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
10/06/2005WO2005092396A1 Composition for medical use having improved water-solubility of peptide and metal-labeling efficiency and preparation for medical use comprising metal-labeled peptide
10/06/2005WO2005092395A1 Radioactive composition and process for producing radioactive composition
10/06/2005WO2005092377A1 Cytotoxicity mediation of cells evidencing surface expression of cd63
10/06/2005WO2005092376A1 Cytotoxicity mediation of cells evidencing surface expression of mcsp
10/06/2005WO2005053752A3 Novel imaging agents comprising caspase-3 inhibitors
10/06/2005WO2005025519A3 Radiolabeled thymidine solid-phase extraction purification method
10/06/2005US20050222677 Coated implantable medical device
10/06/2005US20050222396 Radiolabeled compounds and liposomes and their method of making and using same
10/06/2005US20050220706 Tyrosine kinase type 1 family of receptors; cancer imaging or therapeutic agent targeting to malignant cells ErbB-2 receptor
1 ... 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 ... 243